Advertisement
News
Advertisement

GnRH Agonists: Label Change - Increased Risk of Diabetes and Cardiovascular Disease (Update)(2)

Wed, 10/20/2010 - 1:31pm
U.S. Food & Drug Administration
New information warns about increased risk of diabetes and certain cardiovascular diseases (heart attack, sudden cardiac death, stroke) in men receiving these medications for the treatment of prostate cancer.

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading